Healthcare expenditure in severely depressed patients treated with escitalopram, generic SSRIs or venlafaxine in the UK

References

• Hale AS. ABC of mental health. Depression. BMJ 1997;315:43-6
   Google Scholar
• Angst J. The epidemiology of depressive disorders. Eur Neuropsychopharmacol 1995;5(Suppl):95-8
   PubMed Web of Science ®Google Scholar
• Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:617-27
   PubMed Web of Science ®Google Scholar
• Huang FY, Chung H, Kroenke K, et al. Using the Patient Health Questionnaire-9 to measure depression among racially and ethnically diverse primary care patients. J Gen Intern Med 2006;21:547-52
   PubMed Web of Science ®Google Scholar
• Karasu TB, Gelenberg A, Merriam A, Wang P. American Psychiatric Association practice guidelines for the treatment of patients with major depressive disorder, 2nd edn. Washington, DC: American Psychiatric Press, 2000
   Google Scholar
• First MB. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR™, 2000). 4th edn. Washington, DC: American Psychiatric Association, 2000
   Google Scholar
• Lepine JP, Gastpar M, Mendlewicz J, et al. Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int Clin Psychopharmacol 1997;12:19-29
   PubMed Web of Science ®Google Scholar
• Sonawalla SB, Fava M. Severe depression: is there a best approach?. CNS Drugs 2001;15:765-76
   PubMed Web of Science ®Google Scholar
• Thompson D, Richardson E. Current issues in the economics of depression management. Curr Psychiatry Rep 1999;1:125-34
   PubMedGoogle Scholar
• National Institute for Health and Clinical Excellence. Depression: management of depression in primary and secondary care – NICE guidance. London: National Institute for Health and Clinical Excellence, 2006
   Google Scholar
• Lam RW, Andersen HF. The influence of baseline severity on efficacy of escitalopram and citalopram in the treatment of major depressive disorder: an extended analysis. Pharmacopsychiatry 2006;39:180-4
   PubMed Web of Science ®Google Scholar
• Boulenger JP, Huusom AK, Florea I, et al. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Curr Med Res Opin 2006;22:1331-41
   PubMed Web of Science ®Google Scholar
• Llorca PM, Azorin JM, Despiegel N, et al. Efficacy of escitalopram in patients with severe depression: a pooled analysis. Int J Clin Pract 2005;59:268-75
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Baldwin DS, Blier P, et al. Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol 2007;22:323-9
   PubMed Web of Science ®Google Scholar
• Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005;20:131-7
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Andersen HF, Thase ME. Escitalopram in the treatment of major depressive disorder: a meta-analysis. Curr Med Res Opin 2009;25:161-75
   PubMed Web of Science ®Google Scholar
• Bielski RJ, Ventura D, Chang CC. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 2004;65:1190-6
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Andersen HF. Escitalopram versus venlafaxine XR in the treatment of depression. Int Clin Psychopharmacol 2006;21:297-309
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Huusom AK, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 2004;50:57-64
   PubMed Web of Science ®Google Scholar
• Kienke AS, Rosenbaum JF. Efficacy of venlafaxine in the treatment of severe depression. Depress Anxiety 2000;12(Suppl 1):50-4
   PubMed Web of Science ®Google Scholar
• Danchenko N, Hansen K, Holsten F, Despiegel N. Cost-effectiveness of escitalopram versus citalopram and venlafaxine in treatment of severe depression in Norway [abstract]. 6th World Congress on Health Economics (iHEA) 2007; Copenhagen, Denmark, 2007
   Google Scholar
• Garcia Rodriguez LA, Perez Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 1998;45:419-25
   PubMed Web of Science ®Google Scholar
• Martinez C, Rietbrock S, Wise L, et al. Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study. BMJ 2005;330:389
   PubMed Web of Science ®Google Scholar
• Curtis L, Netten A. Unit costs of health and social care 2006. Personal Social Services Research Unit, University of Kent, Canterbury, UK, 2006
   Google Scholar
• McKinstry B, Walker J, Campbell C, et al. Telephone consultations to manage requests for same-day appointments: a randomised controlled trial in two practices. Br J Gen Pract 2002;52:306-10
   PubMed Web of Science ®Google Scholar
• Pinnock H, McKenzie L, Price D, et al. Cost-effectiveness of telephone or surgery asthma reviews: economic analysis of a randomised controlled trial. Br J Gen Pract 2005;55:119-24
   PubMed Web of Science ®Google Scholar
• National Health Service. Hospital Episode Statistics Online
   Google Scholar
• Joint Formulary Committee. British National Formulary
   Google Scholar
• WHO Collaborating Centre for Drug Statistics Methodology
   Google Scholar
• Glynn RJ, Schneeweiss S, Sturmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 2006;98:253-9
   PubMed Web of Science ®Google Scholar
• Einarson TR, Arikian SR, Casciano J, et al. Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials. Clin Ther 1999;21:296-308
   PubMed Web of Science ®Google Scholar
• Machado M, Iskedjian M, Ruiz I, et al. Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials. Curr Med Res Opin 2006;22:1825-37
   PubMed Web of Science ®Google Scholar
• Shelton C, Entsuah R, Padmanabhan SK, et al. Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo. Int Clin Psychopharmacol 2005;20:233-8
   PubMed Web of Science ®Google Scholar
• Smith D, Dempster C, Glanville J, et al. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 2002;180:396-404
   PubMed Web of Science ®Google Scholar
• Stahl SM, Entsuah R, Rudolph RL. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. Biol Psychiatry 2002;52:1166-74
   PubMed Web of Science ®Google Scholar
• Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-41
   PubMed Web of Science ®Google Scholar
• Benkert O, Grunder G, Wetzel H, et al. A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. J Psychiatr Res 1996;30:441-51
   PubMed Web of Science ®Google Scholar
• Clerc GE, Ruimy P, Verdeau-Palles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group. Int Clin Psychopharmacol 1994;9:139-43
   PubMed Web of Science ®Google Scholar
• Guelfi JD, White C, Hackett D, et al. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J Clin Psychiatry 1995;56:450-8
   PubMed Web of Science ®Google Scholar
• Zanardi R, Franchini L, Serretti A, et al. Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. J Clin Psychiatry 2000;61:26-9
   PubMed Web of Science ®Google Scholar
• Nemeroff CB, Entsuah R, Benattia I, et al. Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol Psychiatry 2008;63:424-34
   PubMed Web of Science ®Google Scholar
• Weinmann S, Becker T, Koesters M. Re-evaluation of the efficacy and tolerability of venlafaxine vs SSRI: meta-analysis. Psychopharmacology (Berl) 2008;196:511-20
   PubMed Web of Science ®Google Scholar
• Wade AG, Toumi I, Hemels ME. A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom. Clin Ther 2005;27:486-96
   PubMed Web of Science ®Google Scholar
• Wade AG, Toumi I, Hemels ME. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK. Curr Med Res Opin 2005;21:631-42
   PubMed Web of Science ®Google Scholar
• Sorensen J, Stage KB, Damsbo N, et al. A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care. Nord J Psychiatry 2007;61:100-8
   PubMed Web of Science ®Google Scholar
• Demyttenaere K, Hemels ME, Hudry J, et al. A cost-effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium. Clin Ther 2005;27:111-24
   PubMed Web of Science ®Google Scholar
• Fernandez JL, Montgomery S, Francois C. Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder. Pharmacoeconomics 2005;23:155-67
   PubMed Web of Science ®Google Scholar